Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPER: enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer
CTR20140772Phase 3Completed
- Sponsor
- Medivation
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzalutamide in prostate cancer (PCa), sponsored by Medivation. Started Mar 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20140772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140772.